Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  MediciNova, Inc.    MNOV


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

MediciNova : Receives Notice of Allowance for New Patent Covering the Combination of MN-166 and Riluzole

share with twitter share with LinkedIn share with facebook
share via e-mail
01/22/2019 | 10:00am EDT

LA JOLLA - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S.

Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover a method of treating a patient diagnosed with ALS, as well as a wide range of other neurodegenerative diseases, with the combination of MN-166 (ibudilast) and riluzole. Other neurodegenerative diseases covered by this patent include Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, Lewy body disease, motor neuron disease, spinal muscular atrophy, myelopathy, traumatic brain injury, spinal cord injury, and many others.

MediciNova was previously granted a U.S. patent which covers the use of MN-166 (ibudilast) as monotherapy for the treatment of amyotrophic lateral sclerosis (ALS) and it expires no earlier than January 2029. MediciNova was previously granted three U.S. patents which cover the use of MN-166 (ibudilast) as monotherapy for the treatment of progressive multiple sclerosis including both primary progressive multiple sclerosis and secondary progressive multiple sclerosis. The first one of these patents expires no earlier than November 2029 and patent term restoration would add 5 years once MN-166 (ibudilast) is approved for progressive multiple sclerosis, extending the patent expiration to November 2034.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, 'We are very pleased to receive notice that this new patent will be granted. We believe it could substantially increase the potential value of MN-166 as it could extend the patent life for the ALS indication by almost 7 years compared to our first ALS patent. In addition, the patent covers a wide range of other neurodegenerative diseases which expands the opportunities for clinical development of MN-166.'

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The nerves lose the ability to trigger specific muscles, which causes the muscles to become weak. As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed. Life expectancy of an ALS patient is usually 2-5 years. According to the ALS Association, there are approximately 20,000 ALS patients in the U.S. and approximately 6,000 people in the U.S. are diagnosed with ALS each year.

About MN-166 (ibudilast)

MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. It attenuates activated glial cells, which play a major role in certain neurological conditions. MN-166 (ibudilast)'s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies, which provide the rationale for treatment of progressive multiple sclerosis (MS) and other neurological diseases such as amyotrophic lateral sclerosis (ALS), substance abuse/addiction and glioblastoma (GBM). MediciNova is developing MN-166 for progressive MS and other neurological conditions such as ALS, substance abuse/addiction, chemotherapy-induced neuropathy, and glioblastoma. MediciNova has a portfolio of patents which cover the use of MN-166 (ibudilast) to treat various diseases including progressive MS, ALS, and drug addiction.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin).

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words 'believes,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'projects,' 'can,' 'could,' 'may,' 'will,' 'would,' 'considering,' 'planning' or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova'scollaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2017 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.


Email: info@medicinova.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MEDICINOVA, INC.
10/07MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN..
09/30MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for th..
09/11MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in..
08/29MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New Y..
08/23MEDICINOVA : Form of prospectus disclosing information, facts, events covered in..
08/23MEDICINOVA INC : Entry into a Material Definitive Agreement, Termination of a Ma..
08/23MEDICINOVA : Effect
08/09MEDICINOVA : Simplified registration form
07/30MediciNova Announces MN-001 Research Collaboration with the National Cerebral..
07/29MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentatio..
More news
Financials (USD)
Sales 2019 12,9 M
EBIT 2019 -7,04 M
Net income 2019 -8,33 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -42,8x
P/E ratio 2020 -15,1x
Capi. / Sales2019 27,4x
Capi. / Sales2020 infx
Capitalization 353 M
Duration : Period :
MediciNova, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDICINOVA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 20,57  $
Last Close Price 8,15  $
Spread / Highest target 170%
Spread / Average Target 152%
Spread / Lowest Target 121%
EPS Revisions
Yuichi Iwaki President, Chief Executive Officer & Director
Jeff Himawan Chairman
Carla Reyes Chief Financial Officer
Kazuko Matsuda Director & Chief Medical Officer
Yutaka Kobayashi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.59.43%19 525
GENMAB32.04%13 439